Novelix calls another board meeting to weigh a new preferential issue
The nano-cap has already raised ₹13.9 crore via preferential allotment and ₹1.7 crore via warrant conversion earlier this year. A fresh issue would add to that.
— 2 earlier stories on Novelix Pharmaceuticals Ltd. →What's new
- The board will meet to consider a new preferential issue of securities.
- Novelix already raised ₹13.9 crore via preferential allotment in February and ₹1.7 crore via warrant conversion in March.
- The meeting will also cover FY26 financial results and a warrant conversion allotment.
Why this matters
A ₹112 crore market cap company going back to the preferential-issuance well within the same fiscal year is the story. The specific size and terms are unknown, but the pattern points to a persistent funding need. The dilution risk for existing holders is the immediate consequence.
What we're watching
- The size and pricing of the new issue once the board decides.
- The stated use of proceeds, especially given the recent capital infusions.
- Any final terms for the pending warrant conversion allotment.
The full read
Novelix Pharmaceuticals is going back to its shareholders for more capital. Its board will meet to consider a new preferential issue, having already raised ₹13.9 crore via the same route in February and ₹1.7 crore through warrant conversion in March. For a company with a market cap of just ₹112 crore, the frequency of capital calls is the key detail. A fresh issue on top of the recent raises will stretch the cap table further. The size and terms are not yet known. The board will also cover FY26 results and the prior warrant allotment. The open question is what this latest raise will cost existing holders.
Questions answered
- What has Novelix raised via preferential routes so far this year?
- The company raised ₹13.9 crore via preferential allotment in February 2026 and ₹1.7 crore through warrant conversion in March 2026.
- What is the company's current market capitalization?
- Novelix is a nano-cap with a market cap of ₹112 crore. A new issue, on top of the recent raises, could materially increase the equity base.
- What else is on the board meeting agenda?
- Besides the new preferential issue, the board will consider the audited financial results for FY26 and approve the allotment of shares from a prior warrant conversion.
- Is this the final decision on the new issue?
- No, this is only an intimation. The actual approval, size, and terms will depend on the board's decision at the upcoming meeting.
Story so far
All notes on TRIMURTHI →- 25 May 2026 · 8:06 PM IST Novelix calls another board meeting to weigh a new preferential issue
- today Novelix signs German deal to commercialize Astaxanthin production
- 2d ago Novelix Pharmaceuticals preps another equity raise